Clinical Scorecard: Sex-Specific Three-Dimensional Echocardiographic Reference Values for the Recreational Athlete's Heart in Relation to VO₂peak Fitness Levels
At a Glance
Category
Detail
Condition
Physiological cardiac adaptations in recreational athletes ('athlete’s heart')
Key Mechanisms
Exercise-induced balanced eccentric enlargement of heart chambers correlated with aerobic fitness (V̇O₂peak), with sex-specific differences in remodeling magnitude
Target Population
Healthy young adults (18–35 years) regularly engaging in recreational physical activity
Three-dimensional echocardiographic (3DE) reference values for left and right heart volumes, mass, and function were established across low, moderate, and high fitness levels based on V̇O₂peak.
Both sexes showed increased heart chamber volumes and left ventricular mass with higher fitness, but women exhibited less pronounced exercise-induced cardiac enlargement than men at comparable V̇O₂peak.
Ratios of heart chamber volumes (LV/RV, LV/LA) remained stable across fitness levels, while LV mass/volume ratio decreased slightly, indicating balanced eccentric cardiac remodeling.
Guideline-Based Recommendations
Diagnosis
Use V̇O₂peak as an objective measure of aerobic fitness to contextualize cardiac size and function in recreational athletes.
Apply sex- and fitness-specific 3DE reference values to distinguish physiological athlete’s heart adaptations from pathological cardiac enlargement.
Consider factors such as sex, body size, age, and fitness level when interpreting echocardiographic findings to avoid misclassification.
Management
Monitor recreational athletes with echocardiography using established fitness- and sex-specific reference values to guide clinical decision-making.
Recognize that physiological cardiac enlargement in recreational athletes is typically balanced and eccentric without functional impairment.
Avoid unnecessary interventions by differentiating physiological adaptations from cardiomyopathies using comprehensive assessment including 3DE and exercise testing.
Monitoring & Follow-up
Regular cardiovascular screening including 3DE echocardiography and cardiopulmonary exercise testing (V̇O₂peak) in recreational athletes to track cardiac adaptations over time.
Monitor changes in LV mass/volume ratio and chamber volumes relative to fitness progression to identify deviations from physiological remodeling.
Use stable volume ratios (LV/RV, LV/LA) as markers to assess balanced cardiac remodeling during follow-up.
Risks
Potential overlap exists between physiological athlete’s heart enlargement and early pathological cardiac conditions, necessitating careful evaluation.
Misinterpretation of exercise-induced cardiac enlargement as pathology may lead to unnecessary restrictions or interventions.
Sex differences in remodeling magnitude require tailored interpretation to avoid under- or over-diagnosis in female athletes.
Patient & Prescribing Data
Young healthy recreational athletes aged 18–35 years with varying fitness levels
No pharmacological treatment indicated; management focuses on accurate diagnosis and monitoring of physiological cardiac adaptations relative to fitness and sex.
Clinical Best Practices
Incorporate V̇O₂peak measurement alongside 3DE echocardiography for comprehensive assessment of the recreational athlete’s heart.
Use sex-specific and fitness-level-specific 3DE reference values to improve diagnostic accuracy and differentiation from cardiac pathology.
Recognize the continuum of cardiac adaptations from untrained to elite athletes and apply this understanding in clinical evaluation.
Maintain awareness of stable chamber volume ratios and decreasing LV mass/volume ratio as hallmarks of physiological remodeling.
Employ advanced imaging techniques such as automated 3DE and speckle tracking echocardiography to enhance differentiation between physiological and pathological changes.
In a nationwide Finnish cohort, patients with atrial fibrillation and gout had higher ischemic stroke rates, while urate-lowering therapy was associated with lower stroke rates.
An ensemble electrocardiogram model classified derived diastolic dysfunction risk phenotypes and stratified heart failure–related death risk across external cohorts, according to findings presented at ASE 2026.